| scholarly article | Q13442814 |
| P2093 | author name string | Mellar P Davis | |
| P433 | issue | 6 | |
| P921 | main subject | pain management | Q621261 |
| P304 | page(s) | 209-219 | |
| P577 | publication date | 2012-07-17 | |
| P1433 | published in | The Journal of Supportive Oncology | Q15763339 |
| P1476 | title | Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain | |
| P478 | volume | 10 |
| Q37264264 | A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates |
| Q38172806 | Achieving effective control in cancer pain: a review of current guidelines |
| Q38104462 | Acute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review. |
| Q91649466 | Aged mice show an increased mortality after anesthesia with a standard dose of ketamine/xylazine |
| Q33714372 | Application of a buprenorphine transdermal patch for the perioperative analgesia in patients who underwent simple lumbar discectomy |
| Q26775658 | Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain |
| Q53080186 | Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. |
| Q57021548 | Buprenorphine for Chronic Pain: a Systemic Review |
| Q38243938 | Buprenorphine for cancer pain: is it ready for prime time? |
| Q53669512 | Buprenorphine for chronic pain. |
| Q38694075 | Buprenorphine--the unique opioid adjuvant in regional anesthesia. |
| Q37722356 | Buprenorphine-naloxone therapy in pain management |
| Q57498749 | Cancer Pain Management: Opioid Analgesics, Part 2 |
| Q47784541 | Converting from Transdermal to Buccal Formulations of Buprenorphine: A Pharmacokinetic Meta-Model Simulation in Healthy Volunteers |
| Q36087227 | Differential Effectiveness of Clinically-Relevant Analgesics in a Rat Model of Chemotherapy-Induced Mucositis |
| Q51529259 | Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. |
| Q34436340 | Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice |
| Q41466780 | Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study |
| Q40883582 | Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain |
| Q64901313 | Essential pharmacologic options for acute pain management in the emergency setting. |
| Q37173960 | Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine |
| Q38387856 | Interpretation of urine drug testing results in patients using transdermal buprenorphine preparations for the treatment of chronic noncancer pain |
| Q27015926 | Laboratory testing for prescription opioids |
| Q37613711 | Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids |
| Q28080140 | Management of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technology |
| Q40561436 | Methadone enhances human influenza A virus replication |
| Q37236111 | Mu opioids and their receptors: evolution of a concept |
| Q38878717 | Opioid Use in Chronic Pain Patients with Chronic Kidney Disease: A Systematic Review |
| Q90673858 | Opioid-induced immunosuppression and carcinogenesis promotion theories create the newest trend in acute and chronic pain pharmacotherapy |
| Q34452255 | Pain management of the cancer patient |
| Q33960633 | Pharmacokinetic comparison of sustained-release and standard buprenorphine in mice. |
| Q38672359 | Pharmacological Management of Cancer-Related Pain |
| Q47752791 | Primary tumour growth in an orthotopic osteosarcoma mouse model is not influenced by analgesic treatment with buprenorphine and meloxicam |
| Q39206999 | Retrospective analysis of 4 years of clinical experience with transdermal buprenorphine (Transtec) in post-traumatic pain |
| Q93048221 | Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain |
| Q42293348 | Safety and efficacy of transdermal buprenorphine versus oral tramadol for the treatment of post-operative pain following surgery for fracture neck of femur: A prospective, randomised clinical study |
| Q40395088 | Shifting blame: Buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America |
| Q38226336 | Sublingual buprenorphine as an analgesic in chronic pain: a systematic review |
| Q36779246 | Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. |
| Q38634946 | The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice |
| Q47556854 | The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine |
| Q38234808 | The clinical analgesic efficacy of buprenorphine |
| Q88992155 | The switch from buprenorphine to tapentadol: is it worth? |
| Q90548695 | Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option |
| Q47592108 | Treating cancer pain: the palliative nursing dilemma |
| Q38282157 | Treatment Considerations for Cancer Pain: A Global Perspective |
| Q92515547 | Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion |
Search more.